BRIEF published on 07/12/2025 at 00:05, 11 months 12 days ago BioNxt Solutions Proposes Convertible Debenture Unit Offering Private Placement Convertible Debenture Investor Information Product Development BioNxt Solutions
BRIEF published on 07/12/2025 at 00:05, 11 months 12 days ago BioNxt Solutions propose une offre d'unités d'obligations convertibles Placement Privé Développement De Produits Informations Pour Les Investisseurs Obligation Convertible Solutions BioNxt
PRESS RELEASE published on 07/12/2025 at 00:00, 11 months 12 days ago BioNxt Solutions Announces Convertible Debenture Unit Private Placement BioNxt Solutions Inc. announces $1.2M non-brokered private placement of convertible debenture units for product development and commercialization Private Placement Convertible Debentures BioNxt Solutions Inc. Commercialization Product Development
BRIEF published on 07/09/2025 at 03:32, 11 months 15 days ago BioNxt Solutions Innovates Targeted Chemotherapy Drug Delivery Precision Oncology Drug Delivery BioNxt Solutions Pharmaceutical Innovations Targeted Chemotherapy
BRIEF published on 07/09/2025 at 03:32, 11 months 15 days ago BioNxt Solutions innove dans l'administration ciblée de médicaments de chimiothérapie Oncologie De Précision Solutions BioNxt Administration De Médicaments Innovations Pharmaceutiques Chimiothérapie Ciblée
PRESS RELEASE published on 07/09/2025 at 03:27, 11 months 15 days ago BioNxt Solutions Introduces Targeted Chemotherapy Drug Delivery Platform for Precision Oncology BioNxt Solutions Inc. announces breakthrough targeted chemotherapy delivery platform for precision oncology, focusing on tumor-specific drug release and neutralization mechanism Precision Oncology BioNxt Solutions Inc. Drug Delivery Targeted Chemotherapy Chemotherapy Market
BRIEF published on 07/07/2025 at 09:10, 11 months 17 days ago BioNxt Advances Sublingual Cladribine Program for MS Pharmaceutical Development Multiple Sclerosis Treatment BioNxt Solutions Sublingual Cladribine Patient Compliance
BRIEF published on 07/07/2025 at 09:10, 11 months 17 days ago BioNxt fait progresser le programme de cladribine sublinguale pour la sclérose en plaques Développement Pharmaceutique Solutions BioNxt Cladribine Sublinguale Conformité Des Patients Traitement De La Sclérose En Plaques
PRESS RELEASE published on 07/07/2025 at 09:05, 11 months 17 days ago BioNxt's Sublingual Cladribine Program for MS Ready for Next Phase BioNxt Solutions receives cladribine API for BNT23001 sublingual thin-film formulation treating multiple sclerosis. Initiates clinical batch production with European partner Gen-Plus GmbH & Co KG Multiple Sclerosis BioNxt Solutions BNT23001 Cladribine API Sublingual Film
BRIEF published on 06/28/2025 at 01:55, 11 months 26 days ago BioNxt Solutions MCTO Revoked by British Columbia Securities Commission Cease Trade Order Annual Filings Trading Resumption Securities Commission BioNxt Solutions
Published on 06/24/2026 at 14:45, 3 hours 26 minutes ago Amdocs Selected by Three Scandinavia to Support Customer Engagement Transformation Across Nordic Markets
Published on 06/24/2026 at 14:00, 4 hours 11 minutes ago GameSquare and U.S. Army Partner for Soldier Showdown 8, Presented by USAA
Published on 06/24/2026 at 14:00, 4 hours 11 minutes ago Adcore Announces Voting Results from Annual Shareholders Meeting
Published on 06/24/2026 at 13:05, 5 hours 6 minutes ago Faraday Copper Reports Drill Results Including Near-Surface Copper Mineralization in the American Eagle Area
Published on 06/24/2026 at 18:05, 6 minutes ago BOS GmbH & Co. KG: Admission of bonds to trading on the Luxembourg Stock Exchange
Published on 06/24/2026 at 17:46, 24 minutes ago GESCO AGM 2026: Proposed resolutions passed by a large majority
Published on 06/24/2026 at 17:40, 31 minutes ago BROADPEAK SA: Descriptif du programme de rachat d’actions propres approuvé par l’assemblée générale du 23 juin 2026
Published on 06/24/2026 at 17:20, 51 minutes ago AL-S Pharma Presents AP-101 Phase 2 Data Supporting Misfolded SOD1 as a Therapeutic Target in ALS at ENCALS 2026
Published on 06/24/2026 at 18:00, 11 minutes ago KERLINK : Assemblée générale mixte des actionnaires du 23 juin 2026 Seconde convocation le 9 juillet 2026.
Published on 06/24/2026 at 17:45, 26 minutes ago Air Liquide poursuit son développement au Kazakhstan avec un investissement clé pour le complexe industriel de Silleno
Published on 06/24/2026 at 17:45, 26 minutes ago Air Liquide continues its long-term growth in Kazakhstan with a key investment to support Silleno's world-scale plant
